Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
The ten-day initiative, running from 10 to 21 November, brings together a team of highly skilled German doctors providing life-changing reconstructive surgeries at no cost
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
This is the first drug to receive a recommendation for this preventative indication in the European Union
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Subscribe To Our Newsletter & Stay Updated